Trial for clinical effi cacy and safety of Selzinc Plus (Pro.Med.CS Praha), comprising selenium, zinc, vitamins A, E and C in patients with chronic non-infectious prostatitis grade IIIA with fertility disorder was performed at the Research Institute of Urology. Th e drug eff ect on time course of patient spermogram parameters was examined. Also selenium concentration measurement in main and control groups was carried out. Symptom time course by scale NIH-CPSI, frequency and severity of symptoms, Sex-4, IPSS, quality of life and the drug impact on parameters of infl ammation in prostate, prostate volume and residual urine volume were considered as secondary criteria. Medication safety was assesed by virtue of analysis of undesirable events frequency, side eff ects and time course of basic serum parameters. As a result of the trial performed it was demonstrated that Selzinc Plus increases sperm cell concentration by 56%, sperm motility by 37%, quantity of ejaculate sperm cells with normal morphology by 18% in patients with chronic noninfectious prostatitis grade IIIA and fertility disorder. Th e drug is safe. No side eff ects or undesirable events were registered during treatment. Selzinc Plus may be recommended for wide application in clinical practice in medical institutions of the Russian Federation.